Israel · Delayed Price · Currency is ILS · Price in ILA InterCure Statistics
Total Valuation
InterCure has a market cap or net worth of ILS 267.44 million. The enterprise value is 396.29 million.
| Market Cap | 267.44M |
| Enterprise Value | 396.29M |
Important Dates
The next estimated earnings date is Monday, December 1, 2025.
| Earnings Date | Dec 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
InterCure has 54.51 million shares outstanding. The number of shares has increased by 8.85% in one year.
| Current Share Class | 54.51M |
| Shares Outstanding | 54.51M |
| Shares Change (YoY) | +8.85% |
| Shares Change (QoQ) | +29.17% |
| Owned by Insiders (%) | 36.44% |
| Owned by Institutions (%) | 6.01% |
| Float | 34.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.10 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.59 |
| EV / Sales | 1.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -21.42 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.85 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -9.69 |
| Interest Coverage | -4.41 |
Financial Efficiency
Return on equity (ROE) is -16.68% and return on invested capital (ROIC) is -9.43%.
| Return on Equity (ROE) | -16.68% |
| Return on Assets (ROA) | -7.74% |
| Return on Invested Capital (ROIC) | -9.43% |
| Return on Capital Employed (ROCE) | -16.81% |
| Revenue Per Employee | 759,759 |
| Profits Per Employee | -221,663 |
| Employee Count | 320 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | -16.50M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.72% in the last 52 weeks. The beta is 0.65, so InterCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -23.72% |
| 50-Day Moving Average | 535.56 |
| 200-Day Moving Average | 548.99 |
| Relative Strength Index (RSI) | 36.91 |
| Average Volume (20 Days) | 73,565 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InterCure had revenue of ILS 243.12 million and -70.93 million in losses. Loss per share was -1.41.
| Revenue | 243.12M |
| Gross Profit | 40.61M |
| Operating Income | -92.40M |
| Pretax Income | -91.09M |
| Net Income | -70.93M |
| EBITDA | -80.62M |
| EBIT | -92.40M |
| Loss Per Share | -1.41 |
Balance Sheet
The company has 51.58 million in cash and 179.34 million in debt, giving a net cash position of -127.76 million or -2.34 per share.
| Cash & Cash Equivalents | 51.58M |
| Total Debt | 179.34M |
| Net Cash | -127.76M |
| Net Cash Per Share | -2.34 |
| Equity (Book Value) | 432.24M |
| Book Value Per Share | 7.59 |
| Working Capital | 172.03M |
Cash Flow
In the last 12 months, operating cash flow was -11.24 million and capital expenditures -7.27 million, giving a free cash flow of -18.50 million.
| Operating Cash Flow | -11.24M |
| Capital Expenditures | -7.27M |
| Free Cash Flow | -18.50M |
| FCF Per Share | -0.34 |
Margins
Gross margin is 16.71%, with operating and profit margins of -38.01% and -29.18%.
| Gross Margin | 16.71% |
| Operating Margin | -38.01% |
| Pretax Margin | -37.47% |
| Profit Margin | -29.18% |
| EBITDA Margin | -33.16% |
| EBIT Margin | -38.01% |
| FCF Margin | n/a |
Dividends & Yields
InterCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.85% |
| Shareholder Yield | -8.85% |
| Earnings Yield | -26.52% |
| FCF Yield | -6.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 8, 2021. It was a reverse split with a ratio of 0.2247564764.
| Last Split Date | Apr 8, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.2247564764 |
Scores
InterCure has an Altman Z-Score of 0.21 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.21 |
| Piotroski F-Score | 4 |